Cancer vaccine - Aixlie

Drug Profile

Cancer vaccine - Aixlie

Alternative Names: HER-2-VAX; HER-2/neu vaccine - Aixlie

Latest Information Update: 14 Aug 2003

Price : $50

At a glance

  • Originator Ohio State University
  • Developer Aixlie Pharmaceuticals; Arkios BioDevelopment International; Ohio State University
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 14 Aug 2003 Discontinued - Phase-I for Breast cancer in USA (unspecified route)
  • 08 Feb 2001 HER-2-VAXTM is available for licensing (http://hometown.aol.com/aixlie/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top